Our results show that while inhibition of Fes kinase activity alone is sufficient to block AML cell growth, inhibitors with dual activity against both Flt3-ITD and Fes are even more active, with IC50 values in the low nM range in multiple Flt3-ITD+ AML cell lines. Here, FES is linked to acute myeloid leukemia.